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Summary 
Adhesion ofB lymphocytes within the different compartments of  secondary lymphoid organs is 
essential  for the function of the humoral immune response. It is not currently known how the 
temporary immobilization orb cells in distinct areas of this complex microenvironment is reg- 
ulated. The present study aimed at defining B cell antigens that initiate binding of  B cells to hu- 
man tonsil sections in situ. Engaging the B cell antigens CD19 and target of an antiprohferative 
antibody 1 (TAPA-1) with monoclonal antibodies induced adhesion of these B cells to the in- 
terfollicular stroma. This binding occurred through the integrin o~4131 on the B cell surface and 
via the extracellular matrix protein fibronectin expressed in the interfollicular compartment of 
the tonsil. Signaling through either antigen, CD19 or TAPA-1, depended on tyrosine kinases. 
Binding induced by engaging CD19 required an intact cytoskeleton, whereas TAPA-l-trans- 
mitted adhesion did not. We suggest that CD19 and TAPA-1 have a novel and unique func- 
tion  by  regulating  an  o~4[31/fibronectin-mediated binding  of B  cells  to  the  interfollicular 
stroma of lymphoid tissues. 
A 
dhesion of  human B lymphocytes within the microen- 
vironment of secondary lymphoid organs is  essential 
for the function of the humoral immune response (1, 2). B 
lymphocytes migrate  through secondary lymphoid organs 
by binding with  their cell-surface adhesion  molecules to 
constitutively expressed ligands within the  different tissue 
compartments (1, 2).  Guided by these "traffic signals"  (1), 
B  cells adhere to and emigrate through the vascular endo- 
thelium and traverse the interfollicular stroma, where they 
make contact with antigen-presenting dendritic cells (3, 4), 
T  cells,  and stromal cells. Activated by signals provided in 
this cellular network (5), B cells migrate into the lymphoid 
follicle, where  they  undergo  antigen-driven  selection  by 
apoptosis  (6).  In  this  complex network built by follicular 
dendritic cells  (FDCs) 1 (7-9),  T  cells,  and other germinal 
center B cells, B cells receive a multitude of signals that de- 
termine whether these cells differentiate into memory cells 
or plasma cells or whether they are eliminated by apoptosis 
(10). Analogous to in vitro-observed adhesion via [31  (11- 
17) and [32 integrins (18,  19),  specificity orb  cell binding 
1Abbreviations used in this paper: ECM, extracellular  matrix; FDC, follicular 
dendritic cell; FN, fibronectin; ICAM, intercellular  adhesion molecule; 
LFA, lymphocyte  function-associated  antigen; TAPA, target of an anti- 
proliferative  antibody;  VCAM, vascular  cell adhesion molecule. 
within these different compartments of the lymphoid tissue 
is presumably influenced by transient activation of adhesion 
molecules  (20).  It is  currently unknown,  however,  what 
determines the temporary immobilization of B  cells in the 
different areas of lymphoid tissues. 
Therefore, we sought to identify B cell antigens that ini- 
tiate binding of  B cells to distinct areas of the lymphoid tis- 
sue.  CD19  and  target  of an  antiproliferative antibody  1 
(TAPA-1, CD81), which, together with CD21 and Leu-13 
(21),  form  a  B  cell  membrane  complex  (22-24),  were 
found to have the unique function of inducing an integrin 
ci4131(very late antigen 4,  CD49d/CD29)-dependent  ad- 
hesion  of B  cells  to  the  interfollicular stroma.  Engaging 
CD19  or TAPA-1  with mAbs  initiated a specific and ty- 
rosine kinase-dependent binding of B  cells  to fibronectin 
(FN).  CD19  and TAPA-1  thus appear to have the novel 
function of directing an  ct4131/FN-mediated immobiliza- 
tion  of B  cells  in  the  interfollicular matrix  of secondary 
lymphoid organs. 
Materials and Methods 
Antibodies and Reagents.  The following antibodies were used: 
5A6 (25) (anti-TAPA-1,  generous gift of S. Levy, Stanford Uni- 
versity, Stanford, CA), anti-o~4137 (26) (generously donated by A. 
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tal and the University of Western Ontario, Ontario, Canada), and 
4B9 (27) (anti-vascular cell adhesion molecule [VCAM]  1, kindly 
given by T.  M.  Carlos,  Division of Hematology,  Harborview 
Medical Center, Seattle, WA). Anti-CD19 (1343, BU12, HD237, 
HD37),  anti-CD21 (BU36,  BU42), anti-CD40 (G285,  HD28), 
HI29 anti-CD53, and anti-CD102 (intercellular  adhesion  mole- 
cule  [ICAM]  2)  were  obtained  from  the  Fifth  International 
Workshop on Human Leukocyte Differentiation Antigens. Rab- 
bit  anti-FN  antiserum  and  rabbit  antilamillin antiserum were 
from  Sigma Chemical Company (St. Louis, MO). mAbs against 
the following antigens were obtained from Dianova-hnmunotech 
(Hamburg,  Germany):  human  IgM,  CD10  (clone  ALB  1), 
CD11a  (25.3.1),  CD18  (BL5), CDl9  (J4.119), CDg0  (BB6), 
CD21 (BL13), CD22 (SJ.10.1H11), CD23 (9P.25), CD29 (Kg0), 
CD32  (2E1), CD37  (BL14), CD40  (MAB89),  CD44  (J173), 
CD45  RA  (ALB11), CD46  (J4-48),  CD49d  (HPg/1),  CD49e 
(SAM1),  CD54  (84H10),  CD58  (AICD58),  CD70  (HNE  51), 
CD72  (J3.109), CD81  (JS64), and FN  (120-5).  All mAbs were 
purified and did not contain sodium azide. Staurosporine  was ob- 
tained from Boehrmger Mannheim (Mannheim, Germany). Genes- 
tein and herbimycin were purchased  from Calbiochem Corp. (La 
Jolla, CA). Cycloheximide,  cytochalasin B, and FN (bovine serum) 
were obtained from Sigma Chemical Co. 
Ceils.  The pre-B cell lines Reh and Nalm-6 were given by 
M.  Mapara  and B.  D6rken  (Max  Delbriick Zentrum, Berlin, 
Germany), and the Burkitt lymphoma cell lines Raft, ILamos, and 
Daudi were a gift of M.  Hummel (Institute of Pathology, Ben- 
jamin Franklin University Hospital,  Berlin, Germany) and of C. 
Schnfidt  (Virchow  University Hospital,  Berlin,  Germany).  All 
cell lines were maintained at 5% CO  2 in 1LPMI 1640 medium 
supplemented with 10% FCS,  1% glutamine, 1% penicillin, and 
1% streptomycin. B cells were freshly isolated from human tonsils 
and were  purified by centrifugation over a Ficoll  gradient and 
subsequent negative selection using anti-CD3-coated magnetic 
beads  (Dynabeads  Dynal, Oslo,  Norway)  according to  the  in- 
structions  of the  manufacturer. As  shown by  flow  cytometry, 
these cell preparations  consisted of >94% pure B cells. 
Frozen  Section Binding Assay.  To  study  B  cell  adhesion to 
tonsils in situ, an in vitro frozen section binding assay (20, 28, 29) 
was  performed with modifications.  Normal human tonsils,  ob- 
tained from routine elective  tonsillectomies,  were  snap  frozen, 
cut,  placed  on  microscope  slides, and dried overnight. B  cells 
were applied at 8 ￿  10  ~' cells/ml in 300 Ixl culture medium (con- 
taining 2.4 mM MgC12) on tissue sections within a 2-cm diameter 
circle  marked with  a  water-repellent "Pap-pen"  (Dako  Corp., 
Carpinteria, CA) and were incubated under rotation (70 revolu- 
tions per min) for 20 min at room temperature. Thereafter,  slides 
were decanted, were fixed for 4-6 h in cold 3% glutaraldehyde/ 
PBS, and were counterstained with hemalaun. Bound cells were 
identified by phase contrast  and light microscopy (￿  Induc- 
tion of tissue binding orB cells by mAbs was assessed by incubat- 
ing cells with purified mAbs (10 pug/ml) in 10% FCS in RPMI 
1640  for  30  min at  4~  with  gentle  rotation.  To  investigate 
whether mAbs had a dose-dependent effect on adhesion,  B cells 
were also treated with different concentrations ofmAbs (5, 1, and 
0.1  b~g/ml). After they were washed  three times,  the cells were 
resuspended  in medium and were applied  to the tissue sections. 
To examine mAbs for their ability to block mAb-induced tissue 
binding of B cells, antibody-treated cells were  incubated with a 
second set of mAbs and were examined for reduced tissue adher- 
ence,  Reduction  of binding was  compared  with  adhesion  of 
mAb-treated cells labeled  with  isotype-matched control mAbs 
and was qualitatively  scored  as complete (no cells bound) or in- 
complete inhibition (significantly fewer cells bound). Induction 
or inhibition of binding  by mAbs was determined in at least three 
separate experiments using as control mAbs isotype-matched and 
B cell-reactive mAbs. 
Assays of Cell Binding to Immobilized Fibronectin.  Antibody-in- 
duced binding of B  cells to  purified FN was  determined using 
plastic-immobilized FN. 24-well plastic plates  (Falcon  Labware, 
Oxnard, CA) were coated with 10 txg/ml FN in PBS for 3 h at 
37~  and were washed extensively with PBS. B cells were treated 
with mAbs, were washed,  and were incubated in triplicates at  / 
X  10  s cells per well for 20 min at 37~  Unbound cells were re- 
moved by three washes with PBS, and adhering cells were fixed 
in 3%  glutaraldehyde/PBS for  10  min at  4~  The  number of 
bound cells per well was detemfined as the mean number of cells 
counted in five representative  high power fields (X400). 
To determine FN-specific binding of mAb-treated cells, FN- 
coated plates were treated  with anti-FN serum (dilution 1:500) 
or with control serum (antilamillin serum, dilution 1 : 500) for 1 h at 
room temperature. Plates were washed extensively before  adding 
the cells. The reduction of binding to plates treated with anti-FN 
was determined in comparison with binding to FN-coated plates 
incubated with control serum.  To test for an integrin ot4-medi- 
ated  adhesion  to FN, mAb-treated cells were labeled with anti- 
a4 mAb and were applied to the plates. Reduction of binding to 
FN by anti-e~4 mAb was determined relative to adhesion  results 
obtained with control mAb (anti-CD20). 
The  involvement of intracellular  pathways  in mAb-induced 
binding of cells to FN was determined with a panel of different 
inhibitors. 8  X  106/ml  cells were incubated for 30 min at 37~ 
with 5% CO2 in media containing 102 nM staurosporine,  50 0,M 
H7, 50 mg/ml genestein, 10 ixg/ml cycloheximide, 1 b~g/ml  her- 
bimycin, or 0.1 mM cytochalasin B, or were treated with control 
media.  Control media had the  same  concentrations of DMSO 
solvent as  were  used  in media containing the  inhibitors. Cells 
were  subsequently treated  as  described  above  with  mAbs and 
were examined for adhesion to FN-coated plates. Reduction of 
binding due to inhibitors was determined relative to adhesion of 
mAh-treated cells incubated with control media. 
lmmunostaining.  Immunophenotyping of  B  cells was  per- 
formed by incubating cells with  10  Dxg/ml of each  mAb for 30 
min at 4~  After washing, cells were labeled with fluoresceinated 
rabbit anti-mouse Ig (Becton Dickinson & Co., Heidelberg, Ger- 
many) and were analyzed by flow cytometry (FacScan  |  Becton 
Dickinson & Co.).  Immunostaining of frozen tissue sections  of 
human tonsils was performed as described (7). Briefly, dried tissue 
sections were fixed for 3 min with acetone, incubated with mAbs 
for  1 h  at room temperature, washed,  and treated  with affinity- 
purified peroxidase-conjugated rabbit anti-mouse Ig (P260; Dako 
Corp.). Antibody reactivity was visualized with 3-amino-9-ethyl- 
carbazole  (Sigma Chemical Co.)  (0.25  mg/ml in 0.1  M  acetate 
buffer, pH 5.0) with 0.003% HgO  2. Tissue sections were counter- 
stained with hemalaun. 
Results 
mAbs against CDI9 and against  TAPA-I  Selectively Induce 
Binding  of  B  Cells  to  the  Inte~follicular  Stroma  of  Tonsil 
Sections.  To determine the adhesion pattern of B  cells on 
tonsil sections and to  identify B  cell antigens that  induce 
this binding, an in vitro adhesion assay on frozen tissue sec- 
1192  Regulation of In Situ Adhesion of B Cells Figure 1.  Treatment orB lymphocytes with anti-CD19 and anti-TAPA-1 mAbs induces binding of these cells to the FN-rich interfollicular stroma of 
tonsil sections. Adhesion assays  were performed as described in Materials and Methods. ￿  (A) Untreated Reh cells bind to the germinal centers of 
lymphoid follicles.  (B) Untreated Raji cells do not adhere to tonsil sections. (C) After incubation of Raji cells with mAbs against CD19, cells bind to the 
interfollicular stroma. The identical binding pattern of Raji cells was observed after treatment of cells with anti-TAPA-1 mAbs. (D) FN is expressed by 
the interfollicular stroma of tonsils as shown by immunoperoxidase staining with an anti-FN rnAb. 
tions  was  used.  B  cells were  incubated  under  rotation  on 
dried tonsil sections, which allowed these cel/s to adhere to 
tissue structures that could be identified under light micros- 
copy. Whereas Reh and Nalm-6 cells bound to the germi- 
nal  centers  of lymphoid follicles (Fig.  1  A  and  Table  1), 
Raji,  Ramos,  Daudi,  and  normal  human  B  cells  did not 
bind to  any area of the  tonsils (Fig.  1  B  and Table  1).  To 
determine cell-surface molecules on B  cells that were able 
to induce binding orB cells to tonsil sections, adhesion was 
tested  after  engaging  cellular  antigens  with  mAbs.  Since 
untreated Raji cells did not adhere to tonsil sections, these 
cells were chosen to examine which mAbs promoted bind- 
ing in situ. To test a broad range of mAbs that showed re- 
activity with Raji cells, a  large number  of available mAbs 
against a  variety of cell-surface antigens with differing cell 
lineage  specificity and  function  was  screened  for  staining 
R.aji  cells  by  flow  cytometry  (data  not  shown).  Among 
these  Raji-reactive mAbs,  only  mAbs  against  CD19  and 
against TAPA-1 induced binding of Raji cells to tonsil sec- 
tions, whereas the other mAbs tested did not initiate adher- 
ence (Table 2). The effect ofanti-CD19 and anti-TAPA-1 
mAbs was reduced in a graded manner with lower concen- 
trations of these mAbs (data not shown). Induction of tissue 
binding,  therefore,  seemed  to  be  a  biologic reaction.  An 
interesting  observation  was  that  m_Abs  against  CD21, 
which, together with CD19,  TAPA-1, and Leu-13, form a 
membrane complex on B  cells (22-24,  30-33),  did not in- 
duce adhesion in situ. Engaging IgM on Raft cells also had 
no effect on binding of these cells. 
Cells treated with anti-CD19  showed  the same binding 
pattern as cells labeled with anti-TAPA-1 mAbs: B  cells in- 
cubated with either of the two mAbs bound exclusively to 
the interfollicular stroma of the tonsil but not to the germi- 
nal centers or to other parts of the lymphoid follicles (Fig. 1 
C).  The induction of adhesion was rapid, since incubation 
of cells with anti-CD19  or with anti-TAPA-1 mAbs for 5 
rain was sufficient to initiate binding (data not shown). 
Next, we examined whether other B  cell lines and nor- 
1193  Behr and Schriever Table 1.  mAb-dependent Binding Pattern of B Cells to Tonsil Sections and Antigen Expression of B Cells 
B cells 
Raji  Daudi  Reh*  Nalm-6*  Ramos  Normal B cells 
Binding to tonsils after treatment 
Isotype control antibodies  ..... 
anti-CD20  ..... 
anti-CD19  IS  IS  IS  IS  - 
anti-CD21  ..... 
anti-TAPA-  1 (CD81)  IS  IS  IS  IS  - 
Cell surface antigen expression 
of untreated cells 
Isotype control antibodies  ..... 
CDlla (LFA-lcx)  +++  +++  ++  ++  ++ 
CD19  ++  +++  ++  +++  +++ 
CD20  +++  ++  ++  -  +++ 
CD21  +++  +++  +++  -  + 
CD29 (B1)  +++  +++  +++  +++  + 
CD49c (el3)  ....  + 
CD49d (cx4)  +++  +++  +++  +++  + 
CD49e (oL5)  -  -  -  + + +  + 
TAPA-1 (CD81)  ++  +++  +  +++  +++ 










Cell surface antigen expression of untreated cells was determined by flow cytometry.  The level of antigen expression was graded by the mean peak 
channel (-, <~20; +, 21-115; ++, 116--200; +++,  ~>201)on a three-log scale of fluorescence intensity. 
*Reh and Nalm-6 cells also showed binding to the germinal centers of lymphoid follicles. 
IS, binding to interfollicular stroma. 
Table 2.  mAB-dependent  Binding of Raji Cells to Human 
Tonsil Sections 
Binding to the 
interfollicular stroma  No binding 
mAbs against CD19, 
TAPA-1 (CD81) 
mAbs  against  IgM,  CD10,  CDlla 
(LFA-lo0,  CD18  (LFA-132),  CD20, 
CD21,  CD22,  CD23,  CD29  (131), 
CD32 (Fc~/RII), CD37, CD40, CD44, 
CD45RA, CD46, CD49d (o~4), CD53, 
CD54  (ICAM-1),  CD58  (LFA-3), 
CD70,  CD72,  CD102  (ICAM-2), 
Act-i (ee4137) 
An identical adhesion pattern was induced by five different anti-CD19 
antibodies  04-119, B43, BU12, HD237, HD37) and by two different 
TAPA-I mAbs (5A6 andJS69).  Since Raft cells expressed only lgM but 
not IgG, IgD, or IgA, induction of adhesion by anti-lg was tested using 
an anti-IgM mAb. No adherence was exerted by isotype-matched con- 
trol mAbs. Results shown are representative  of at least three indepen- 
dent experiments. 
mal B  cells bound as well to tonsils after engaging CD19 or 
TAPA-1 with mAbs. Daudi, Reh,  and Nalm-6 cells could 
also  be  induced to  adhere  to  the  interfollicular stroma  by 
anti-CD19  or  by  anti-TAPA-1  mAbs  but  not  by  anti- 
CD20 or by anti-CD21 antibodies. The characteristic prop- 
erty of Reh and Nalm-6 ceils to bind to the germinal cen- 
ter  remained  unaffected  by  antibody  treatment,  however 
(Table 1). Ramos cells and normal B  cells, in contrast,  did 
not show any binding to the tonsil sections after treatment 
with anti-CD19 or with anti-TAPA-1 mAbs (Table 1). 
To  investigate whether  this  lack  of response  of Ramos 
cells and normal B  cells to the anti-CD19 or anti-TAPA-1 
treatment  could  be  correlated  with  low  levels  of distinct 
antigens, B  cells were examined for expression of a panel of 
cell-surface molecules (Table 1). Whereas Ramos cells and 
normal B  cells did not differ markedly from the  other cell 
hnes in their expression of CD19  or TAPA-1, they exhib- 
ited reduced levels of integrin c~4 chain (CD49d)  and inte- 
grin 131 chain (CD29). 
Anti-CD19-induced  Binding of Raji  Cells  to the  Interfollic- 
ullar Stroma Involves Integrin 0e4131 on the B  Cell Surface.  To 
identify  adhesion  molecules  on  Raji  cells  that  were  in- 
volved  in  the  anti-CD19-induced  binding,  mAbs  were 
examined for their ability to block tissue adherence ofanti- 
CD19-treated  cells  (Table  3).  For  this  purpose,  anti- 
1194  Regulation of In Situ Adhesion of B Cells Table 3.  Inhibition  of Anti-CD19 mAb-induced Adhesion of Raji Cells to lntetfollicular Stroma of Tonsil Sections by mAbs 
Complete  Partial  No inhibition of  binding 
mAb against  mAb against 
CD49d (a4)  CD29 (131) 
mAbs against  IgM,  CD10,  CDlla  (LFA-lo~),  CD18 
(LFA-[32), CD19, CD20, CD21, CD22, CD23, CD32 
(Fc~/!Kll),  CD37,  CD40,  CD44,  CD45RA,  CD46, 
CD49e (c~5), CD53, CD54 (ICAM-1), CD58 (LFA-3), 
CD70,  CD72,  TAPA-1  (CD81),  CD102  (ICAM-2), 
CD106 (VCAM-1), Act-1 (et4137) 
Inhibition of tissue binding of anti-CD19-treated  cells by mAbs was determined relative to binding of anti-CD19-treated  cells incubated with iso- 
type-matched and B cell-reactive mAbs. Results shown are representative of at least three independent experiments. 
CD19-1abeled  Raft  ceils  were  incubated  with  a  panel  of 
different  B  cell-reactive  mAbs and were  applied  to tissue 
sections.  Only antibodies against the integrin o~4 chain and 
against the integrin  [31  chain inhibited binding completely 
and partially,  respectively,  whereas  the  other mAbs tested 
did not impair adhesion in situ. 
Anti-CD19  and  anti-TAPA-1  mAbs  Induce an  Integrin 
ee4---mediated Binding of B Cells to Purified Fibronectin.  Next, 
we aimed at defining the receptor to which anti-CD19 and 
anti-TAPA-l-induced  B  cells  were binding.  The  forego- 
ing observations demonstrated that o~4{31 on B cells was in- 
volved in the anti-CD19-induced binding to the interfol- 
licular  stroma.  VCAM-1  (CD106)  and  the  extracellular 
matrix  (ECM)  protein  FN have been identified  as ligands 
for c14131 (34,  35).  These antigens  differ markedly in their 
tissue  distribution,  as  shown  by immunostaining.  Consis- 
tent with  earlier reports  (20,  36),  VCAM-1  was preferen- 
tially found on FDCs within the germinal centers (data not 
shown).  FN, in contrast, was strongly expressed by stromal 
cells  located in the interfollicular region of lymphoid folli- 
cles  (Fig.  1  D).  This  tissue  distribution  of FN  correlated 
closely with the areas where anti-CD19- and anti-TAPA- 
1-treated Raft cells  adhered  (Fig.  1,  C  and D). This led to 
the assumption that binding of ot4131 to one of its  ligands, 
FN, was responsible for the in situ binding of Rail cells ini- 
tiated by anti-CD19 and by anti-TAPA-1 mAbs. To verify 
this,  we examined binding of mAb-treated B  cells  to puri- 
fied FN. 
To study the effect of antibody treatment on adhesion of 
B  cells to purified  FN, lkaji  and R.amos cells were treated 
with mAbs against CD19,  CD20,  CD21,  or TAPA-1  and 
were  examined  for  adhesion  to  plastic-immobilized  FN 
(Fig.  2).  FN- and c~4-specific binding was  defined by the 
ability to block adhesion to FN with an anti-FN serum and 
an anti-o~4  mAb, respectively. Using this assay, anti-CD19- 
or  anti-TAPA-l-treated  FLaji cells  demonstrated  an  FN- 
specific binding that could also be blocked significantly by 
anti-cl4.  In  contrast,  anti-CD20-  or  anti-CD21--labeled 
l:(aji  cells  lacked  FN/ot4-specific  adhesion.  Ramos  cells, 
treated with  any of the mAbs, failed to show FN/cx4-spe- 
cific binding. 
Induction of B  Cell Binding to Purified Fibronectin by Anti- 
CD19 and by Anti-TAPA-1 mAbs Requires Different Intracel- 
lular Pathways.  To identify the intracellular signals  involved 
in  the  anti-CD19  and  anti-TAPA-l-induced  binding  of 
Raft cells  to purified FN, inhibitors of defined intracellular 
pathways  were  used  (Fig.  3).  Binding  of anti-CD19  or 
anti-TAPA-l-treated Raft cells  to FN was significantly re- 
duced by genestein and herbimycin  (inhibitors  of tyrosine 
kinases)  or  by  staurosporine  (an  inhibitor  of protein  ki- 
nases).  In  contrast,  cycloheximide  and  H7  (inhibitors  of 
protein synthesis and.of protein kinase  C, respectively)  did 
not  impair  binding  of  anti-CD19-  or  anti-TAPA-1- 
labeled cells.  A  marked difference in inhibition  of binding 
was observed when Raft  cells,  treated  with  anti-CD19  or 
with anti-TAPA-1  mAbs, were incubated with cytochala- 
sin B  (an inhibitor of the  cytoskeleton).  While binding of 
anti-CD19-treated cells to FN was strongly reduced by cy- 
tochalasin B, no effect was seen with this inhibitor on anti- 
TAPA-l-labeled Raft cells. 
Discussion 
The present study showed that engaging CD19 or TAPA-1 
on human B  lymphocytes with rnAbs induced adhesion of 
these cells  to the interfollicular stroma of human tonsils by 
initiating  binding  of  integrin  ot4[31  to  its  ligand  FN. 
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Figure  2.  lKaji cells treated with anti-CD19 and with anti-TAPA-1 
mAbs adhere via el4 to immobilized FN. Specificity  of  binding was dem- 
onstrated using an anti-FN antiserum and an anti-ct4 mAb to block bind- 
ing sites on the FN layer and on the B cells, respectively. The percentage 
of  inhibition by anti-FN and anti-co4  was determined relative to the num- 
ber of adhering cells treated with negative control antibodies (antilaminin 
antiserum and auti-CD20 mAb, respectively). Results are the mean -+ SD 
of  three independent experiments. 
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Figure 3.  R.equirements of intracellular pathways for anti-CD19- and 
anti-TAPA-l-induced adhesion ofP,  aji cells to FN. Binding after engag- 
ing CD19  and TAPA-1  was reduced by inhibitors of tyrosine kinases 
(genestein and herbimycin) and by blockade of protein kinases (staurospo- 
fine), but not by an inhibitor of protein kinase C (HT) and not by inhibi- 
tion of protein synthesis (cycloheximide). In contrast to anti-TAPA-1- 
treated cells, anti-CDl9-incubatecl  cells did not bind in the presence of 
an inhibitor of the cytoskeleton (cytochalasin B). The percentage of inhi- 
bition of binding was determined relative to the number ofadhefing cells 
in DMSO control medium (without inhibitors). Results are the mean --- 
SD of three independent experiments.  [],  control; C], anti-CD21;  ", 
anti-CD19;  [], anti-TAPA-1 (CD81). 
mAbs against CD19  or against TAPA-1  induced  this bind- 
ing  phenomenon  on  l:Laji  cells.  Other  B  cell  lines,  i.e., 
Daudi,  Nalm-6,  and  R.eh  cells,  showed  the  same binding 
pattern,  whereas  Ramos  cells and  normal B  cells failed to 
respond  to  incubation  with  anti-CD19  or  anti-TAPA-1 
mAbs. Using inhibitors  of intracellular pathways, we could 
show  that signals generated  through  either antigen,  CD19 
or TAPA-1, needed the action of tyrosine kinases to facili- 
tate the ot4131/FN-mediated  binding.  Adhesion initiated by 
signaling  through  CD19  required  an  intact  cytoskeleton, 
whereas  binding  induced  by  engaging  TAPA-I  did  not. 
This  study  demonstrates  that  the  B  cell surface  molecules 
CD19  and  TAPA-1  appear to have the  unique  and  novel 
function of inducing an ~4131/FN-mediated  adhesion orB 
cells to the interfollicular stroma of lymphoid tissues. 
In the current study, a frozen section adhesion  assay was 
used  to  identify  B  cell  antigens  that  initiate  binding  of B 
cells to human tonsils. An important advantage of this assay 
was that it allowed detection  of cellular binding to a tissue 
matrix that may resemble the  microenvironment  encoun- 
tered  by these  cells in  vivo.  In fact,  results  obtained  with 
this assay could be confirmed with experiments using phys- 
iologic conditions  (29).  In previous studies,  this device was 
helpful to explain the adherence  of leukocytes to high en- 
dothelial venules (28, 29) and to describe the adhesion orb 
cells  to  the  germinal  centers  (20,  37,  38).  Adhesion  of B 
cells to germinal centers of lymphoid follicles, for example, 
was  found  to be mediated by tx4~l  on  the  B  cell  surface 
and by VCAM-1  expressed on FDCs (20, 37). Since not all 
cell lines  that were positive for e~4~1  bound  to the germi- 
nal  center,  the  existence  of other  cellular  structures  that 
mediate this adhesion  was postulated.  The results obtained 
in  the  present  study  supported  these  earlier  findings  by 
showing that the cell lines Nalm-6 and Reh adhered to the 
germinal centers, while resting normal B  cells and the B cell 
lines P,.aji,  Ramos,  and Daudi  did not bind  to these struc- 
tures.  These  results  and  pilot studies  using  mAbs to block 
germinal  center  binding  (38)  were  helpful,  demonstrating 
that  the  frozen  tissue  assay  used  in  our study  was  a  valid 
method to detect adhesion through  the e~4131 receptor. 
CD19  and TAPA-1  have a central role for B  cell physi- 
ology. These molecules, together with the complement re- 
ceptor  CD21  (CR2)  and  Leu-13,  constitute  a  membrane 
complex on B  cells that regulates  several important  B  cell 
functions  (22-24,  30-33).  Each  component  of this  com- 
plex influences  independently  the activation,  proliferation, 
and function orb  cells (22, 39).  For example, cross-linking 
CD19  to membrane  lgM on B  cells lowered the threshold 
for antigen  receptor-dependent  stimulation  of B  cells (32). 
Other  reports  demonstrated  that  ligation  of CD19  on  B 
cells induced  or blocked proliferation  and  antibody  secre- 
tion,  depending  on  the  stimulating  signal  used  (30).  The 
CD21/CD19/TAPA-1  complex is relevant also for the ad- 
hesion orB cells, since engaging these molecules with mAbs 
induced  homotypic binding.  Whereas  the  anti-CD19-ini- 
dated aggregation occurred through LFA-l-dependent  and 
-independent  mechanisms  (40,  41),  the  anti-TAPA-1- 
mediated  binding  was  entirely  independent  of leukocyte 
function-associated  antigen  (LFA)  I  (24).  However,  ho- 
motypic adhesion could also be observed by engaging vari- 
ous  other  B  cell  antigens  (41).  Induction  of aggregation, 
therefore,  did  not  appear  to  be  a  phenomenon  that  was 
specific  for  signaling  through  the  CD21/CD19/TAPA-1 
complex. 
Our  observations  provide  evidence  for  a  novel  and 
unique  role of CD19 and TAPA-1  in mediating B  cell ad- 
hesion to ECM components.  Among a large panel ofmAbs 
tested,  only  mAbs  against  CD19  or  against  TAPA-1  in- 
duced  binding  of B  cells  to  the  interfollicular  stroma  of 
tonsils.  This  indicated  that  the  CD21/CD19/TAPA-1 
complex  could  have  the  specific  function  of initiating  B 
cell adhesion to lymphoid stroma in situ.  It was interesting 
to note that signaling through  CD21  did not induce bind- 
ing of B  cells to tissue or to purified FN. This finding con- 
trasts with observations that mAb binding to each  compo- 
nent  of the  complex  generated  similar biologic  effects by 
inducing  cellular  aggregation  with  identical  morphology 
(23). Obviously, the o~4~3  I/FN-mediated adhesion that was 
studied  in  our  assays was different  from homotypic  adhe- 
sion and did not occur through signals generated via CD21. 
Furthermore,  anti-CD19- and anti-TAPA-l-induced  bind- 
ing could also be observed with  Nalm-6  cells that did not 
express  CD21  (Table  1).  It  can  be  concluded,  therefore, 
that the CD21  subunit of the CD21/CD 19/TAPA- 1 com- 
plex was not required  to transmit signals that ted to B  celt 
binding via cx4~I/FN. 
To  further  dissect  the  signals  generated  by  CD19  and 
TAPA-1,  we  defined  the  intracellular  pathways  that were 
necessary to mediate the e~4131/FN adhesion. Binding initi- 
ated through  either molecule,  CD19 or TAPA-1, involved 
the action of tTrosine kinases, since genestein and herbimy- 
cin  inhibited  adhesion  after  engaging  CD19  or  TAPA-1 
1196  Regulation of In Situ Adhesion  of B Cells with mAbs.  Protein kinase  C  and protein synthesis were 
not involved in this signal  transduction, since H7 and cy- 
cloheximide, respectively, did not affect cellular adhesion 
initiated by mAb binding to CD19 and TAPA-1. This sig- 
nal  transduction  was  similar,  though,  to  the  intracellular 
pathways  that  were  involved in  the  homotypic adhesion 
initiated through several B  cell antigens  (41).  We did not 
investigate, however, whether induction of 0c4[31/FN-me- 
diated,  heterotypic adhesion  and  initiation  of homotypic 
adhesion are two separate events triggered by the same sig- 
nal, i.e., engaging CD19 and TAPA-1 on the cell surface of 
B cells. 
The current study identified integrin c14131 as the recep- 
tor for the  anti-CD19-  and anti-TAPA-l-induced bind- 
ing. Adhesion of anti-CD19-treated cells to tonsil sections 
could  be  inhibited  completely by  mAbs  against  the  ix4 
chain and partially by mAbs against  the [31 chain. Since the 
anti-el4 mAb abrogated binding more effectively than the 
anti-[31  mAb, it is possible that adhesion occurred mainly 
through the 0L4 chain of the ~x4131 heterodimer complex. 
0~4137 and c14131 contain the same 0e4 chain, and both bind 
to  FN  in  vitro  (42).  An  anti-0r  n-tAb did not  reduce 
anti-CD19-  and  anti-TAPA-l-induced  adhesion,  how- 
ever. It is possible that this antibody is directed against  an 
epitope not involved in the anti-CD19- and anti-TAPA- 
1-induced binding to FN.  Support for this interpretation 
comes from observations that distinct epitopes on c~4137 are 
responsible  for adhesion  of o~4137 to  its  different ligands, 
VCAM-1, mucosal addressin-1, and FN (43). 
We  could also  demonstrate that FN was  the ligand for 
binding of anti-CD19- and anti-TAPA-l-treated B  cells. 
In  contrast  to  Raft  cells  that  were  incubated  with  anti- 
CD20  or anti-CD21  mAbs  or with  isotype-control anti- 
bodies,  only  anti-CD19  and  anti-TAPA-l-labeled  cells 
showed  FN-specific  adhesion.  In  addition,  this  adhesion 
could be blocked using an anti-0~4 mAb.  Results of these 
binding  experiments  using  purified  FN  were  therefore 
consistent with the observations obtained in the frozen sec- 
tion assay that demonstrated an ci4131-specific tissue adher- 
ence only after engaging CD19 or TAPA-1  on the B  cell 
surface.  It was  surprising  to note that although  Raft cells 
expressed el4131 before antibody treatment, untreated cells 
did not adhere to the FN-rich interfollicular stroma of ton- 
sils and also  did not bind  to purified FN.  A  quantitative 
change of the 0e4131 receptor thus appears to be an unlikely 
cause for the anti-CD19- and anti-TAPA-l-induced bind- 
ing. It seems plausible, instead, that on untreated B cells the 
adhesiveness of the c14131 receptor for its ligand FN was too 
low to facilitate binding. Engaging CD19 or TAPA-1 with 
mAbs, in contrast, seems to significantly increase the avidity 
oflx4[31/FN adhesion. 
This hypothesis is supported by several reports about an- 
tigen-dependent modulation  of [31-mediated adhesion  to 
ECM components.  Induction of binding of T  cells to FN 
via [31 integrins could be observed, for example, by antigen 
stimulation  (14),  by  signaling  through  CD50  (ICAM-3) 
(15),  or by cross-linking the T  cell receptor (17).  In addi- 
tion,  adherence  of leukocytes  to  ECM  was  induced  by 
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anti-[31  mAbs  (44).  Similarly,  signaling  via  CD7  on NK 
cells induced a [31 integrin-mediated adhesion of these cells 
to FN (13).  Since the expression levels of the [31 integrins 
remained unchanged after induction of  binding, an increase 
of the avidity of the integrin receptor was considered to be 
the likely cause for the adhesion.  Faull et al.  (12)  defined 
two  distinct mechanisms  that were responsible for an in- 
crease of[31-mediated binding ofT cells to FN: First, affin- 
ity of the ci4131 receptor towards FN was increased by en- 
gaging  [31  with  an  mAb.  Second,  treating the  cells  with 
PMA induced binding to  FN by altering events that oc- 
curred after occupancy of the [31 receptor without affecting 
its affinity. These postreceptor events could be specifically 
blocked by cytochalasin D, an inhibitor of the cellular cy- 
toskeleton.  Likewise,  modulation  of the  receptor affinity 
(45) and postreceptor events (46) have been described to be 
the basis for increased adhesion through the integrins elL[32 
(LFA-1, CD1 la/CD 18). 
Data obtained in the present study support the interpre- 
tation that signaling through CD19 and TAPA-1  initiated 
two different models of increasing adhesiveness of 0~4131/ 
FN binding.  Using cytochalasin B, an inhibitor of the cy- 
toskeleton, we demonstrated that binding induced by en- 
gaging  CD19  required  the  action  of the  cytoskeleton, 
whereas adhesion initiated via TAPA-1 was independent of 
the cytoskeleton. It is therefore likely that the signals gen- 
erated through CD19 are involved in regulating postrecep- 
tor events. Engaging TAPA-1, in contrast, may lead to an 
increase of the affinity of 0~4131 towards FN. 
Several observations deserve further comment. The fact 
that  Ramos  cells  and  normal B  cells  did not  respond  to 
treatment with  mAbs  against  CD19  and  against  TAPA-1 
could not be explained by a lack of the  two antigens  on 
these  cells.  Instead,  the  expression levels  for ci4  and  [31 
were significantly lower on these cells than on the other B 
cells  tested.  It seems possible,  therefore, that Ramos  cells 
and normal B cells failed to demonstrate inducible binding 
via c14131/FN  because  the  amount of o~4131 on  their cell 
surface did not permit adhesion through this receptor. Ear- 
lier findings that resting normal B cells also fail to adhere at 
the  germinal center via ~x4131/VCAM-1  (20)  support the 
idea that appropriate stimuli or other yet undefined associ- 
ated structures further influence the CD19  and TAPA-1- 
initiated binding through 0~4131/FN. 
It  was  also  surprising  to  note  that,  although  engaging 
CD19  or TAPA-1  induced 0e4[31-mediated  binding orB 
cells  to  FN,  germinal  center  binding  via  VCAM-1  re- 
mained unaltered on Reh and Nalm-6 cells and could not 
be induced on other cells (Table 1). A possible explanation 
for  this  observation  might  be  that  engaging  CD19  and 
TAPA-1  initiated an adhesion of oL4131 to only one of its 
ligands,  FN, whereas signaling through these and other B 
cell molecules had no effect on binding ofoL4131 to its other 
ligand, VCAM-1. 
Our  observations  provide  grounds  for  a  hypothetical 
model that may help to explain some new aspects  of B cell 
physiology. These data represent the first  description of a 
receptor-dependent regulation of  B cell adhesion to the in- terfollicular  compartment  of secondary  lymphoid  tissues. 
We propose that  CD19  and TAPA-1  supply B  cells with 
rapid and unique signals that result in temporary immobili- 
zation of B  cells within the stromal matrix. By binding to 
ECM  components,  these  cells may receive further  signals 
that  define their differentiation and function  (11).  Within 
this  microenvironment,  adhering B  cells might  also  form 
contact  with  T  cells of the  interfollicular area  and  could 
thereby influence the function  of these T  ceils. Recently, 
CD77  has been  identified as  a  potential ligand for CD19 
(47).  Since  CD77  is  constitutively expressed  on  germinal 
center B  cells entering apoptosis (48), the CD19-CD77  in- 
teraction may have  an  important impact on  the fate  of B 
cells in secondary lymphoid organs, Future studies will fo- 
cus on how receptor-regulated adhesion of B  cells to ECM 
determines B  cell function. 
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